Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention : A Pilot Randomized Clinical Trial
© 2017, The American College of Clinical Pharmacology..
Myocardial injury following elective percutaneous coronary intervention (PCI) occurs in about one-third of patients and is associated with mortality. Platelet aggregation, thrombosis formation, and inflammation are the main causes of cardiac injury during PCI. Vitamin D plays a key role in the cardiovascular system by exerting antiplatelet, anticoagulant, and anti-inflammatory properties. There is no published study that investigated the effect of vitamin D in the prevention of cardiac injury following elective PCI. In a randomized clinical trial, 99 patients admitted for elective PCI were randomized into vitamin D (n = 52) and control (n = 47) groups. The intervention group received 300 000 IU vitamin D orally 12 hours before PCI. The cardiac biomarkers were checked at baseline, 8 and 24 hours after PCI. hs-CRP was also measured at baseline and after 24 hours. The increase in CK-MB was documented in 20 patients (42%) in the control group and 18 patients (34.6%) in the intervention group (P = .417). Furthermore, the increase in cTnI occurred in 4 patients (8%) and 2 patients (3.3%) in the control and intervention groups, respectively (P = .419). No significant changes were noted in the level of cardiac biomarkers. In the vitamin D group, the mean difference in CK-MB between 8 and 24 hours was significantly lower (P = .048). The mean difference in hs-CRP was significantly lower in the vitamin D group (P = .045). This study could not show a clear effect of vitamin D in the prevention of cardiac injury during elective PCI. Further outcome-based studies are needed to describe the role of vitamin D in the prevention of periprocedural myocardial injury.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacology - 58(2018), 2 vom: 15. Feb., Seite 144-151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aslanabadi, Naser [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.01.2019 Date Revised 15.01.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcph.989 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM27513993X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM27513993X | ||
| 003 | DE-627 | ||
| 005 | 20231225005015.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcph.989 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0917.xml |
| 035 | |a (DE-627)NLM27513993X | ||
| 035 | |a (NLM)28841229 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aslanabadi, Naser |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention |b A Pilot Randomized Clinical Trial |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2019 | ||
| 500 | |a Date Revised 15.01.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017, The American College of Clinical Pharmacology. | ||
| 520 | |a Myocardial injury following elective percutaneous coronary intervention (PCI) occurs in about one-third of patients and is associated with mortality. Platelet aggregation, thrombosis formation, and inflammation are the main causes of cardiac injury during PCI. Vitamin D plays a key role in the cardiovascular system by exerting antiplatelet, anticoagulant, and anti-inflammatory properties. There is no published study that investigated the effect of vitamin D in the prevention of cardiac injury following elective PCI. In a randomized clinical trial, 99 patients admitted for elective PCI were randomized into vitamin D (n = 52) and control (n = 47) groups. The intervention group received 300 000 IU vitamin D orally 12 hours before PCI. The cardiac biomarkers were checked at baseline, 8 and 24 hours after PCI. hs-CRP was also measured at baseline and after 24 hours. The increase in CK-MB was documented in 20 patients (42%) in the control group and 18 patients (34.6%) in the intervention group (P = .417). Furthermore, the increase in cTnI occurred in 4 patients (8%) and 2 patients (3.3%) in the control and intervention groups, respectively (P = .419). No significant changes were noted in the level of cardiac biomarkers. In the vitamin D group, the mean difference in CK-MB between 8 and 24 hours was significantly lower (P = .048). The mean difference in hs-CRP was significantly lower in the vitamin D group (P = .045). This study could not show a clear effect of vitamin D in the prevention of cardiac injury during elective PCI. Further outcome-based studies are needed to describe the role of vitamin D in the prevention of periprocedural myocardial injury | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CK-MB | |
| 650 | 4 | |a cTnI | |
| 650 | 4 | |a hs-CRP | |
| 650 | 4 | |a percutaneous coronary intervention | |
| 650 | 4 | |a periprocedural myocardial injury | |
| 650 | 4 | |a vitamin D | |
| 650 | 7 | |a Vitamins |2 NLM | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Creatine Kinase, MB Form |2 NLM | |
| 650 | 7 | |a EC 2.7.3.2 |2 NLM | |
| 700 | 1 | |a Jafaripor, Iraj |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi, Selda |e verfasserin |4 aut | |
| 700 | 1 | |a Hamishehkar, Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Ghaffari, Samad |e verfasserin |4 aut | |
| 700 | 1 | |a Toluey, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Hanieh |e verfasserin |4 aut | |
| 700 | 1 | |a Entezari-Maleki, Taher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g 58(2018), 2 vom: 15. Feb., Seite 144-151 |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2018 |g number:2 |g day:15 |g month:02 |g pages:144-151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.989 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2018 |e 2 |b 15 |c 02 |h 144-151 | ||